Secondary Logo

Journal Logo

Protocol Alert

doi: 10.1097/01.COT.0000470879.00415.07
News
Free
Figure

Figure

Clinical trials recently added to the National Cancer Institute's database

Back to Top | Article Outline

BRAIN/CNS TUMORS

18F-FLT PET Imaging in Assessing Tumors and Measuring Response in Younger Patients With Brain Tumors

Phase: Phase II

Type: Diagnostic

Age: 21 and under

Trial IDs: PBTC-N12, NCI-2013-00805, NCT01244737

FDOPA-PET/MRI in Measuring Tumors before Surgery in Patients with Gliomas

Phase: No phase specified

Type: Diagnostic

Age: 18 and over

Trial IDs: 201502019, NCI-2015-00411, NCT02371031

Ferumoxytol in Improving MR Imaging in Patients with High-Grade Brain Tumors or Cerebral Metastases

Phase: No phase specified

Type: Diagnostic

Age: 18 and over

Trial IDs: 813, NCI-2015-00226, NCT00980720, ONC-03095-LX, OHSU-813, 6537, NCI-6537, OHSU-8097, NCT00103038

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: 08109, NCI-2011-01701, NCT00823459

Back to Top | Article Outline

BREAST CANCER

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Phase: Phase II

Type: Treatment

Age: Over 18

Trial IDs: REP0114, NCI-2015-00934, 2014-004796-23, NCT02370238

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: NSABP FB-11, NCI-2015-00998, WI180455, NCT02296801

HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients with Advanced Triple Negative Breast Cancer

Phase: Phase I

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: 9876, NCI-2015-00866, NCT02474173

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: A8641020, NCI-2015-00961, 2014-002286-30, NCT02299635

Black Cohosh in Treating Patients with Breast Ductal Carcinoma in Situ

Phase: No phase specified

Type: Supportive care, Treatment

Age: 18 and over

Trial IDs: 1205010204, NCI-2015-00920, NCT01628536

Breast Magnetic Resonance Imaging in Determining Surgical Margins in Patients With Newly Diagnosed Breast Cancer Undergoing Breast Conserving Therapy or Surgery

Phase: No phase specified

Type: Diagnostic

Age: 18 and over

Trial IDs: 11-330, NCI-2012-00256, NCT01568346

Denosumab in Treating Patients with Breast Cancer and Bone Metastases

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: 2013-0007, NCI-2014-01273, NCI-2014-01069, NCT01952054

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer

Phase: Phase III

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: NRG-BR003, NCI-2015-00128, NRG-BR1428, NCT02488967

Effects of Chemotherapy on Intestinal Bacteria in Patients with Newly Diagnosed Breast Cancer

Phase: No phase specified

Type: Biomarker/Laboratory analysis, Natural history/Epidemiology

Age: 18 and over

Trial IDs: 1B-14-6, NCI-2014-02611, HS-14-00712, NCT02370277

FES-PET/CT in Predicting Treatment Response in Patients with Endocrine Refractory, Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer

Phase: No phase specified

Type: Diagnostic

Age: 18 and over

Trial IDs: UPCC 20114, NCI-2015-01008, 821717, NCT02409316

Back to Top | Article Outline

ENDOMETRIAL CANCER

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Phase: Phase II

Type: Treatment

Age: 18 and over

Trial IDs: GOG-3007,

NCI-2015-00993, CRAD001CUS236T, NCT02228681

Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors

Phase: No phase specified

Type: Supportive care

Age: Not specified

Trial IDs: OSU-13005,

NCI-2014-00770, 18240, 2013C0043, NCT02465541

Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Endometrial Cancer

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: PHL-086, NCI-2013-00890, NCT01815151, 9322,

NCT01935934

Back to Top | Article Outline

GASTROINTESTINAL CANCERS

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: 15608, NCI-2015-01087, 2014-003791-23, I4T-MC-JVDB, NCT02443883

Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer

Phase: Phase II, Phase I

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Phase: Phase III

Type: Treatment

Age: 18 and over

Trial IDs: 3475-061, NCI-2015-00922, 2014-005241-45, NCT02370498

Afatinib and Paclitaxel in Treating Patients with HER2-Positive Recurrent Advanced Gastric, Gastroesophageal Junction, or Esophageal Cancer

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: AAAM5905,

NCI-2015-00758, 1200.203,

NCI-2014-02350,

NCT02274012

Domperidone in Treating Patients with Gastrointestinal Disorders

Phase: Phase III

Type: Treatment

Age: 16 and over

Trial IDs: 2012-0261,

NCI-2012-02093,

NCT01696734

Fludeoxyglucose F-18 PET/MRI in Predicting Treatment Response in Patients with Newly Diagnosed Stage II or III Rectal Cancer Undergoing Chemoradiation Therapy

Phase: Phase II

Type: Diagnostic

Age: 18 and over

Trial IDs: 155513,

NCI-2015-00980, 133123, NCT02233595

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Phase: No phase specified

Type: Treatment

Age: 18 and over

Trial IDs: TO-TAS-102-401,

NCI-2015-00157,

NCT02286492

Back to Top | Article Outline

HEAD & NECK/ORAL CANCER

Home-Based Monitoring System in Reducing Dehydration in Patients with Head and Neck Cancer Undergoing Radiation Therapy

Phase: No phase specified

Type: Supportive care

Age: 18 and over

Trial IDs: 2013-0535, NCI-2015-00946, NCT02253238

Everolimus, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Cancer

Phase: Phase I

Type: Treatment

Age: 18 and over

Trial IDs: 09-342, NCI-2010-00294, NCT01058408

Back to Top | Article Outline

HEMATOLOGIC CANCERS

A Phase 1, Dose-Finding Study of CC-90002,in Subjects With Advanced Solid and Hematologic Cancers

Phase: Phase I

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: CC-90002-ST-001, NCI-2015-00963, NCI-2015-00964, NCT02367196

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Phase: Phase I

Type: Natural history/Epidemiology

Age: 55 and under

Trial IDs: CCT-HPDSC-001, NCI-2015-00045, NCT00596999

Activated Immune Cells in Treating Patients with Hematologic Cancers That Have Relapsed after Donor Stem Cell Transplant

Phase: Phase I

Type: Treatment

Age: 18 and over

Trial IDs: J1484, NCI-2015-00990, NCT02342613

Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases

Phase: Phase II, Phase I

Type: Treatment

Age: 70 and under

Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825

Bortezomib in Preventing Graft-Versus-Host Disease After Reduced-Intensity Donor Stem Cell Transplant in Patients With Hematologic Malignancies

Phase: Phase II

Type: Treatment

Age: 18 to 75

Trial IDs: 12-404, NCI-2013-00623, NCT01754389

CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies

Phase: Phase I

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: CC-486-CAGEN-001, NCI-2015-00973, NCT02223052

Cyclophosphamide, Fludarabine Phosphate, and Donor White Blood Cells Treating Patients With Hematologic Malignancies That Relapsed After a Previous Donor Stem Cell Transplant

Phase: Phase II

Type: Treatment

Age: 1 and over

Trial IDs: MT2003-15, NCI-2010-01695, 2004LS006, NCT00303693, NCT00167180

Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies

Phase: Phase II

Type: Treatment

Age: 70 and under

Trial IDs: EXCESS, NCI-2012-00806, H-27251, NCT01189786

Donor Stem Cell Transplant in Treating Patients with Hematological Malignancy

Phase: No phase specified

Type: Treatment

Age: 55 and under

Trial IDs: MT2001-02, NCI-2010-02154, 0107M05202, 2001LS049, NCT00393133, NCT00176930

GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 to 75

Trial IDs: GS-US-218-1502, NCI-2014-02679, 2014-002475-29,

NCT02254421

Gene Expression Profiling in Tissue, Blood, or Bone Marrow Samples From Patients With Lymphoid Malignancies

Phase: No phase specified

Type: Biomarker/Laboratory analysis

Age: Not specified

Trial IDs: 02-C-N042, NCI-2013-02038, 02-CN-042 E, 999902042, NCT00339963

Gene Transfer Therapy in Treating Patients With Beta-Thalassemia Undergoing Autologous Hematopoietic Stem Cell Transplant or Blood Transfusion

Phase: Phase I

Type: Biomarker/Laboratory analysis, Treatment

Age: 15 and over

Trial IDs: 10-164, NCI-2012-01725, NCT01639690

Filgrastim-Stimulated Bone Marrow Transplant in Treating Patients with Hematological Malignancies without Matched Donors

Phase: No phase specified

Type: Treatment

Age: Under 22

Trial IDs: 21819, NCI-2014-01418, 0159-2004, 159-2004 (G-CSF PMRD Feasibility), CR6_IRB00021819, EMORY IRB # 21819, G-CSF PMRD, NCT00228813

Early Palliative Care in Improving Quality of Life and Reducing Symptom Burden in Patients with Hematologic Malignancies Undergoing Stem Cell Transplant and Their Caregivers

Phase: No phase specified

Type: Supportive care

Age: 18 and over

Trial IDs: 14-241, NCI-2014-02035, NCT02207322

Back to Top | Article Outline

LEUKEMIA/LYMPHOMA/MDS

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Phase: Phase II

Type: Biomarker/Laboratory analysis, Treatment

Age: 18 and over

Trial IDs: ARO-006,

NCI-2015-00952,

NCT02283177

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase: Phase III

Type: Supportive care, Treatment

Age: 18 and over

Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated Acute Myeloid Leukemia (AML)

Phase: Phase I

Type: Treatment

Age: 18 and over

Trial IDs: MCC 18157, NCI-2015-00988, 15.05.0004, NCT02403310

A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase: Phase III

Type: Treatment

Age: 18 and over

Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase: Phase III

Type: Supportive care, Treatment

Age: 18 and over

Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated Acute Myeloid Leukemia (AML)

Phase: Phase I

Type: Treatment

Age: 18 and over

Trial IDs: MCC 18157, NCI-2015-00988, 15.05.0004, NCT02403310

A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase: Phase III

Type: Treatment

Age: 18 and over

Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Phase: No phase specified

Type: Treatment

Age: 18 and over

Trial IDs: B1871040, NCI-2014-01005, 2013-000691-15, NCT01903733

Cladribine, Cytarabine, and Filgrastim in Combination with Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

Phase: Phase II, Phase I

Type: Treatment

Age: 18 to 70

Trial IDs: 201505084,

NCI-2015-00828,

NCT02416908

Collecting and Storing Blood, Bone Marrow, and Other Samples from Patients with Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Phase: No phase specified

Type: Tissue collection/Repository

Age: Not specified

Trial IDs: CALGB 9665, NCI-2009-00497, CDR0000271412,

NCT00899223

DNA in Blood and Bone Marrow Samples From Young Patients with Acute Lymphoblastic Leukemia

Phase: No phase specified

Type: Biomarker/Laboratory analysis, Tissue collection/Repository

Age: 1 to 30

Trial IDs: AALL08B2, NCI-2011-02200, CDR0000659101, COG-AALL08B2, NCT01016379

Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase: No phase specified

Type: Treatment

Age: 28 days to 17 years

Trial IDs: 20130320, NCI-2015-00115, NCT02187354

Gemtuzumab Ozogamicin, Busulfan, and Cyclophosphamide Before Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Juvenile Myelomonocytic Leukemia

Phase: Phase I

Type: Treatment

Age: 30 and under

Trial IDs: CHNY-01-515,

NCI-2010-02364,

NCT00669890

Collecting and Storing Blood, Bone Marrow, and Other Samples from Patients with Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Phase: No phase specified

Type: Tissue collection/Repository

Age: Not specified

Trial IDs: CALGB 9665,

NCI-2009-00497, CDR0000271412,

NCT00899223

DNA in Blood and Bone Marrow Samples From Young Patients with Acute Lymphoblastic Leukemia

Phase: No phase specified

Type: Biomarker/Laboratory analysis, Tissue collection/Repository

Age: 1 to 30

Trial IDs: AALL08B2, NCI-2011-02200, CDR0000659101, COG-AALL08B2, NCT01016379

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!